WO2003028710A3 - Verbindungen zur reduzierung übermässiger nahrungsaufnahme - Google Patents

Verbindungen zur reduzierung übermässiger nahrungsaufnahme Download PDF

Info

Publication number
WO2003028710A3
WO2003028710A3 PCT/EP2002/010805 EP0210805W WO03028710A3 WO 2003028710 A3 WO2003028710 A3 WO 2003028710A3 EP 0210805 W EP0210805 W EP 0210805W WO 03028710 A3 WO03028710 A3 WO 03028710A3
Authority
WO
WIPO (PCT)
Prior art keywords
food
compounds
excessive intake
reducing excessive
reducing
Prior art date
Application number
PCT/EP2002/010805
Other languages
English (en)
French (fr)
Other versions
WO2003028710A2 (de
Inventor
Michael Paul Pieper
Joachim Mierau
Original Assignee
Boehringer Ingelheim Pharma
Michael Paul Pieper
Joachim Mierau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Michael Paul Pieper, Joachim Mierau filed Critical Boehringer Ingelheim Pharma
Priority to JP2003532043A priority Critical patent/JP2005504110A/ja
Priority to AU2002337135A priority patent/AU2002337135A1/en
Priority to EP02772350A priority patent/EP1438047A2/de
Priority to CA002461586A priority patent/CA2461586A1/en
Publication of WO2003028710A2 publication Critical patent/WO2003028710A2/de
Publication of WO2003028710A3 publication Critical patent/WO2003028710A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Dopamin- Rezeptoragonisten zur Herstellung eines Arzneimittels zur Reduzierung übermäßiger Nahrungsaufnahme.
PCT/EP2002/010805 2001-09-28 2002-09-26 Verbindungen zur reduzierung übermässiger nahrungsaufnahme WO2003028710A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003532043A JP2005504110A (ja) 2001-09-28 2002-09-26 食物の過剰摂取量を低減させる化合物
AU2002337135A AU2002337135A1 (en) 2001-09-28 2002-09-26 Compounds for reducing excessive intake of food
EP02772350A EP1438047A2 (de) 2001-09-28 2002-09-26 Verbindungen zur reduzierung übermässiger nahrungsaufnahme
CA002461586A CA2461586A1 (en) 2001-09-28 2002-09-26 Compounds for the reduction of excessive food intake

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10148233A DE10148233A1 (de) 2001-09-28 2001-09-28 Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
DE10148233.7 2001-09-28

Publications (2)

Publication Number Publication Date
WO2003028710A2 WO2003028710A2 (de) 2003-04-10
WO2003028710A3 true WO2003028710A3 (de) 2003-09-12

Family

ID=7700867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010805 WO2003028710A2 (de) 2001-09-28 2002-09-26 Verbindungen zur reduzierung übermässiger nahrungsaufnahme

Country Status (9)

Country Link
US (7) US20030087941A1 (de)
EP (1) EP1438047A2 (de)
JP (1) JP2005504110A (de)
AU (1) AU2002337135A1 (de)
CA (1) CA2461586A1 (de)
DE (1) DE10148233A1 (de)
PE (1) PE20030628A1 (de)
UY (1) UY27459A1 (de)
WO (1) WO2003028710A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
DE10312809A1 (de) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
NZ547152A (en) * 2003-10-16 2009-12-24 Neurosearch As Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
CA2553649A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
EP1708707A1 (de) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem n-methyl-d-aspartat (nmda)-rezeptorantagonisten
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US7754770B2 (en) * 2005-06-27 2010-07-13 Mason Chemical Company Antimicrobial composition
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
EP2193024A4 (de) * 2007-09-25 2013-11-06 Entrotech Inc Farbersatzfilme, verbundstoffe daraus und verwandte verfahren
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
WO2010030887A1 (en) 2008-09-11 2010-03-18 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
US20130045987A1 (en) * 2010-05-03 2013-02-21 Dignity Health Novel methods of use of tetrahydroberberine (thb)
RU2665134C2 (ru) * 2012-05-07 2018-08-28 Омерос Корпорейшн Лечение зависимости и расстройств побуждений с применением ингибиторов фдэ7
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855306A (en) * 1987-04-10 1989-08-08 Sandoz Ltd. Uses of dopamine receptor agonists
WO1990013294A1 (en) * 1989-05-09 1990-11-15 Whitby Research, Inc. A method of reducing body weight and food intake using a dopamine d2 receptor agonist
WO1999025328A1 (en) * 1997-11-14 1999-05-27 Warner-Lambert Company (+)-ephedrine as a sympathomimetic drug
WO1999059563A2 (en) * 1998-05-15 1999-11-25 Pharmacia & Upjohn Company Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
EP1051971A1 (de) * 1999-05-10 2000-11-15 Pierce Management, L.L.P. Pflaster und Verfahren zur transdermalen Verabreichung von Bupropion als freie base
EP1099441A2 (de) * 1999-11-10 2001-05-16 Pfizer Products Inc. Zusammensetzungen enthaltend Apo-B-Sekretion/MTP Inhibitoren und Mittel gegen Fettleibigkeit und deren Verwendung
WO2001041763A1 (en) * 1999-12-10 2001-06-14 University Of Cincinnati Treatment of addiction disorders
US20010016582A1 (en) * 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
WO2002060423A2 (en) * 2001-01-29 2002-08-08 Otsuka Pharmaceutical Co., Ltd. Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004990A (en) * 1994-06-03 1999-12-21 Zebra Pharmaceuticals Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855306A (en) * 1987-04-10 1989-08-08 Sandoz Ltd. Uses of dopamine receptor agonists
WO1990013294A1 (en) * 1989-05-09 1990-11-15 Whitby Research, Inc. A method of reducing body weight and food intake using a dopamine d2 receptor agonist
US20010016582A1 (en) * 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
WO1999025328A1 (en) * 1997-11-14 1999-05-27 Warner-Lambert Company (+)-ephedrine as a sympathomimetic drug
WO1999059563A2 (en) * 1998-05-15 1999-11-25 Pharmacia & Upjohn Company Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
EP1051971A1 (de) * 1999-05-10 2000-11-15 Pierce Management, L.L.P. Pflaster und Verfahren zur transdermalen Verabreichung von Bupropion als freie base
EP1099441A2 (de) * 1999-11-10 2001-05-16 Pfizer Products Inc. Zusammensetzungen enthaltend Apo-B-Sekretion/MTP Inhibitoren und Mittel gegen Fettleibigkeit und deren Verwendung
WO2001041763A1 (en) * 1999-12-10 2001-06-14 University Of Cincinnati Treatment of addiction disorders
WO2002060423A2 (en) * 2001-01-29 2002-08-08 Otsuka Pharmaceutical Co., Ltd. Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DOMINO EDWARD F ET AL: "Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 325, no. 2-3, 1997, pages 137 - 144, XP001121783, ISSN: 0014-2999 *
EMILIEN G ET AL: "DOPAMINE D3 AGONISTS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 11, no. 11, 2001, pages 1713 - 1728, XP001057496, ISSN: 1354-3776 *
FERNANDEZ-LOPEZ J-A ET AL: "PHARMACOLOGICAL APPROACHES FOR THE TREATMENT OF OBESITY", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 62, no. 6, 2002, pages 915 - 944, XP009001892, ISSN: 0012-6667 *
IHARA T ET AL: "SINGLE AND REPEATED ORAL DOSE TOXICITY STUDIES WITH TALIPEXOLE DIHYDROCHLORIDE (B-HT 920 CL2) IN CYNOMOLGUS MONKEYS", OYO YAKURI - PHARMACOMETRICS, XX, XX, vol. 46, no. 6, 1993, pages 401 - 416, XP009001922, ISSN: 0300-8533 *
NAGASHIMA MARIKO ET AL: "Hyperthermia induced by the dopamine D-1 receptor agonist SKF 38393 in combination with the dopamine D-2 receptor agonist talipexole in the rat.", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 43, no. 4, 1992, pages 993 - 997, XP009003332, ISSN: 0091-3057 *
TERRY P ET AL: "DOPAMINE RECEPTOR SUBTYPE AGONISTS AND FEEDING BEHAVIOR", OBESITY RESEARCH, BATON ROUGE, LA,, US, vol. 3, no. SUPPL 4, November 1995 (1995-11-01), pages 515S - 523S, XP001062494, ISSN: 1071-7323 *
WILLNER P ET AL: "Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.", PSYCHOPHARMACOLOGY. GERMANY AUG 1994, vol. 115, no. 4, August 1994 (1994-08-01), pages 454 - 462, XP009003272, ISSN: 0033-3158 *

Also Published As

Publication number Publication date
AU2002337135A1 (en) 2003-04-14
US20030087941A1 (en) 2003-05-08
PE20030628A1 (es) 2003-07-15
EP1438047A2 (de) 2004-07-21
WO2003028710A2 (de) 2003-04-10
US20060223869A1 (en) 2006-10-05
US20060030607A1 (en) 2006-02-09
US20080051444A1 (en) 2008-02-28
US20080051443A1 (en) 2008-02-28
DE10148233A1 (de) 2003-04-10
US20050032843A1 (en) 2005-02-10
JP2005504110A (ja) 2005-02-10
UY27459A1 (es) 2003-04-30
CA2461586A1 (en) 2003-04-10
US20050032812A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2003028710A3 (de) Verbindungen zur reduzierung übermässiger nahrungsaufnahme
TWI350831B (en) Process for the preparation of ring compounds
HUE037069T2 (hu) Eljárás nagy tisztaságú 2,4'-metiléndifenildiizocianát elõállítására
WO2007146248A3 (en) Stable laquinimod preparations
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
AU2003265589A1 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
HK1108580A1 (en) A process for the preparation of [1,4,5]-oxadiazepine derivatives
WO2004105773A3 (en) Use of s1p
HUP0201336A3 (en) The use of nmda antagonist compounds for producing medicaments useful for prophylaxis of dyskinesias
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
EG23381A (en) Production of olefins.
EG23393A (en) Production of olefins.
AU2003245880A1 (en) Process for the preparation of thioalkylamine derivatives
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
AU2003265373A1 (en) Preparation of aztreonam
AU2003276330A1 (en) Novel compounds comprising a thiocarbonyl-sulfanyl group, which can be used for the radical synthesis of alpha-perfluoroalkylamines
WO2003005970A3 (en) Carvedilol polymorph
AU2003249964A1 (en) A process for the preparation of 2-acetoxymethyl-4 halo-but-1-yl acetates
AU2003223098A1 (en) Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
AU2003286316A1 (en) 5-aminophenanthridine derivatives as npy-5 antagonists
AU2003242538A1 (en) Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2002337634A1 (en) Process for the preparation of bupropion hydrochloride
AU2003223104A1 (en) A process for the preparation of indolymaleimides
AU2003275360A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2461586

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003532043

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002772350

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002772350

Country of ref document: EP